Ignite Creation Date:
2024-05-06 @ 4:14 PM
Last Modification Date:
2025-12-17 @ 8:21 AM
Study NCT ID:
NCT04920383
Status:
None
Last Update Posted:
2024-03-01 00:00:00
First Post:
2021-06-03 00:00:00
Brief Title:
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
Sponsor:
Alpine Immune Sciences Inc
Organization:
Alpine Immune Sciences, Inc.
Study Overview
Official Title:
An Open-label Study of ALPN-202 Combined With PD-1 Inhibition in Subjects With Advanced Malignancies (NEON-2)
Status:
None
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NEON-2
Brief Summary:
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-3475-D05KEYNOTE-D05 | OTHER | Merk Sharp Dohme LLC | None |